PARIS, France—Investigators designing ISAR-REACT 5, the first head-to-head trial of ticagrelor and prasugrel in ACS patients heading for revascularization, expected to prove that ticagrelor is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback